S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   424.15 (-0.40%)
AAPL   166.96 (-0.62%)
MSFT   406.34 (-1.34%)
META   504.99 (+2.19%)
GOOGL   156.51 (+0.67%)
AMZN   179.49 (-0.99%)
TSLA   150.45 (-3.22%)
NVDA   846.01 (+0.67%)
AMD   154.76 (+0.48%)
NIO   4.01 (+2.56%)
BABA   68.91 (+0.13%)
T   16.25 (+0.81%)
F   12.04 (+0.00%)
MU   113.23 (-2.66%)
GE   154.21 (-0.94%)
CGC   8.15 (+25.58%)
DIS   112.91 (-0.03%)
AMC   2.92 (-2.01%)
PFE   25.32 (-0.39%)
PYPL   62.29 (-1.53%)
XOM   118.25 (-0.32%)
S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   424.15 (-0.40%)
AAPL   166.96 (-0.62%)
MSFT   406.34 (-1.34%)
META   504.99 (+2.19%)
GOOGL   156.51 (+0.67%)
AMZN   179.49 (-0.99%)
TSLA   150.45 (-3.22%)
NVDA   846.01 (+0.67%)
AMD   154.76 (+0.48%)
NIO   4.01 (+2.56%)
BABA   68.91 (+0.13%)
T   16.25 (+0.81%)
F   12.04 (+0.00%)
MU   113.23 (-2.66%)
GE   154.21 (-0.94%)
CGC   8.15 (+25.58%)
DIS   112.91 (-0.03%)
AMC   2.92 (-2.01%)
PFE   25.32 (-0.39%)
PYPL   62.29 (-1.53%)
XOM   118.25 (-0.32%)
S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   424.15 (-0.40%)
AAPL   166.96 (-0.62%)
MSFT   406.34 (-1.34%)
META   504.99 (+2.19%)
GOOGL   156.51 (+0.67%)
AMZN   179.49 (-0.99%)
TSLA   150.45 (-3.22%)
NVDA   846.01 (+0.67%)
AMD   154.76 (+0.48%)
NIO   4.01 (+2.56%)
BABA   68.91 (+0.13%)
T   16.25 (+0.81%)
F   12.04 (+0.00%)
MU   113.23 (-2.66%)
GE   154.21 (-0.94%)
CGC   8.15 (+25.58%)
DIS   112.91 (-0.03%)
AMC   2.92 (-2.01%)
PFE   25.32 (-0.39%)
PYPL   62.29 (-1.53%)
XOM   118.25 (-0.32%)
S&P 500   5,006.78 (-0.31%)
DOW   37,724.92 (-0.08%)
QQQ   424.15 (-0.40%)
AAPL   166.96 (-0.62%)
MSFT   406.34 (-1.34%)
META   504.99 (+2.19%)
GOOGL   156.51 (+0.67%)
AMZN   179.49 (-0.99%)
TSLA   150.45 (-3.22%)
NVDA   846.01 (+0.67%)
AMD   154.76 (+0.48%)
NIO   4.01 (+2.56%)
BABA   68.91 (+0.13%)
T   16.25 (+0.81%)
F   12.04 (+0.00%)
MU   113.23 (-2.66%)
GE   154.21 (-0.94%)
CGC   8.15 (+25.58%)
DIS   112.91 (-0.03%)
AMC   2.92 (-2.01%)
PFE   25.32 (-0.39%)
PYPL   62.29 (-1.53%)
XOM   118.25 (-0.32%)
Free Trial

eFFECTOR Therapeutics (EFTR) News Today

→ Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad)
Free EFTR Stock Alerts
$1.82
-0.07 (-3.96%)
(As of 02:21 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
globenewswire.com logoeFFECTOR Therapeutics to Participate in Upcoming Investor Conference
globenewswire.com - April 9 at 8:00 AM
marketwatch.com logoEFFECTOR Therapeutics Shares Drop as Development of Lung Cancer Treatment Drug Ends
marketwatch.com - April 4 at 2:30 PM
markets.businessinsider.com logoEFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC
markets.businessinsider.com - April 4 at 2:30 PM
finance.yahoo.com logoCancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
finance.yahoo.com - April 4 at 2:30 PM
marketbeat.com logo
marketbeat.com - April 4 at 10:34 AM
marketbeat.com logo
marketbeat.com - April 4 at 9:51 AM
globenewswire.com logoeFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
globenewswire.com - April 4 at 8:30 AM
marketbeat.com logo
marketbeat.com - April 4 at 8:29 AM
markets.businessinsider.com logoBuy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin Trials
markets.businessinsider.com - March 28 at 4:32 PM
finanznachrichten.de logoeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 27 at 10:58 PM
investorplace.com logoEFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
investorplace.com - March 25 at 10:03 PM
globenewswire.com logoeFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - March 25 at 4:01 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)
markets.businessinsider.com - March 19 at 11:53 AM
markets.businessinsider.com logoBuy Rating Affirmed for eFFECTOR Therapeutics Amid Promising Oncology Drug Milestones and Extended Financial Runway
markets.businessinsider.com - February 6 at 9:21 PM
msn.com logoeFFECTOR Therapeutics Regains Nasdaq Compliance Status
msn.com - January 31 at 2:01 PM
finance.yahoo.com logoDoes eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
finance.yahoo.com - January 30 at 12:44 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - January 25 at 6:53 PM
marketbeat.com logo
marketbeat.com - January 12 at 6:00 AM
finanznachrichten.de logoeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Announces Reverse Stock Split
finanznachrichten.de - January 10 at 9:32 AM
msn.com logoeFFECTOR Therapeutics announces 1-for-25 reverse stock split
msn.com - January 9 at 12:17 PM
msn.com logoeFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study
msn.com - December 8 at 3:04 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
finance.yahoo.com - December 8 at 10:04 AM
msn.com logoeFFECTOR stock rises after FDA fast track status for breast cancer therapy
msn.com - November 28 at 10:40 AM
markets.businessinsider.com logoBuy Rating for eFFECTOR Therapeutics Based on Promising Drug Developments and Capital Security
markets.businessinsider.com - November 17 at 9:59 AM
msn.com logoeFFECTOR Therapeutics GAAP EPS of -$0.13 misses by $0.01
msn.com - November 13 at 7:57 PM
tmcnet.com logoeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
tmcnet.com - November 13 at 7:57 PM
fool.com logoeFFECTOR Therapeutics (NASDAQ: EFTR)
fool.com - September 20 at 7:50 PM
msn.com logoHC Wainwright starts eFFECTOR at buy, cites drug technology platform
msn.com - August 25 at 10:45 PM
nasdaq.com logoHC Wainwright & Co. Initiates Coverage of eFFECTOR Therapeutics (EFTR) with Buy Recommendation
nasdaq.com - August 24 at 10:36 PM
markets.businessinsider.com logoeFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer Candidates
markets.businessinsider.com - August 24 at 5:36 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR) and Brainsway (BWAY)
markets.businessinsider.com - August 24 at 6:52 AM
benzinga.com logoeFFECTOR Therapeutics Chief Executive Officer Acquires 33,799 Shares After Exercising Company Stock Options
benzinga.com - August 14 at 6:44 PM
finance.yahoo.com logoeFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022)
finance.yahoo.com - August 11 at 6:34 PM
markets.businessinsider.com logoMizuho Securities Reaffirms Their Buy Rating on eFFECTOR Therapeutics (EFTR)
markets.businessinsider.com - August 9 at 12:57 AM
finance.yahoo.com logoeFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 7:55 PM
finance.yahoo.com logoeFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
finance.yahoo.com - June 8 at 4:40 PM
msn.com logoeFFECTOR Therapeutics to launch ~$8.7M registered direct offering
msn.com - June 7 at 10:17 AM
marketwatch.com logoeFFECTOR Therapeutics Shares Fall Premarket After Stock Sale >EFTR
marketwatch.com - June 7 at 10:17 AM
finance.yahoo.com logoInvestors in eFFECTOR Therapeutics (NASDAQ:EFTR) from a year ago are still down 35%, even after 77% gain this past week
finance.yahoo.com - June 3 at 1:57 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - May 31 at 6:27 PM
msn.com logoStifel Upgrades eFFECTOR Therapeutics (EFTR)
msn.com - May 26 at 11:02 PM
msn.com logoWhy eFFECTOR Therapeutics Shares Trading Higher Today
msn.com - May 26 at 1:01 PM
msn.com logoeFFECTOR soars as Stifel upgrades after Phase 2 data for cancer drug combo
msn.com - May 26 at 1:01 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - May 26 at 1:01 PM
investorplace.com logoWhy Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today?
investorplace.com - May 26 at 9:10 AM
markets.businessinsider.com logoeFFECTOR Therapeutics (EFTR) Gets a Buy from Mizuho Securities
markets.businessinsider.com - May 26 at 2:30 AM
tmcnet.com logoeFFECTOR Therapeutics Reports Positive Data Updates from Phase
tmcnet.com - May 25 at 9:24 PM
finance.yahoo.com logoeFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
finance.yahoo.com - May 25 at 9:24 PM
msn.com logoCredit Suisse Maintains eFFECTOR Therapeutics (EFTR) Outperform Recommendation
msn.com - May 12 at 8:08 PM
finanznachrichten.de logoeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - May 10 at 3:52 AM
Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

EFTR Media Mentions By Week

EFTR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EFTR
News Sentiment
▼
0.00

0.49
▲
Average
Medical
News Sentiment

EFTR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EFTR Articles
This Week
▼
0

1
▲
EFTR Articles
Average Week

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:EFTR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
1970’s computer coder issues shocking A.I. warning
TradeSmith